International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 03 Issue 08 August 2023

Page No: 1719-1722

DOI: https://doi.org/10.47191/ijmscrs/v3-i8-52, Impact Factor: 6.597

Dermatitis Herpetiformis: Clinical Exploration, Underlying Pathogenesis and Therapeutic Advances

Patricia Flores Troche[1], Salmahk Karen Avilés Tenorio[2], Jaime Picazo Luna[3], Maria Reyna Lara Guevara[4], Néstor Daniel Rodriguez Trujillo[5], Diana Karina Conejo Chávez[6]

[1]Hospital General Regional 200 Tecamac Instituto Mexicano del Seguro Social. Residente de medicina interna/UNAM Universidad Latina de México.

[2]Instituto Mexicano del Seguro Social. Hospital General de Zona 14 La Paz. Guadalajara, Jalisco, México.

[3]Hospital General de Zona 194 Instituto Mexicano del Seguro Social. Naucalpan de Juárez, México.

[4]Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Clínica hospital Irapuato, Guanajuato, México.

[5,6]Instituto Politécnico Nacional, Campus Celaya. Celaya, México.

ABSTRACT

Dermatitis herpetiformis (DH) emerges as a chronic, immune-mediated, systemic skin pathology closely linked to celiac disease (CD). Characterized by polymorphous and pruritic cutaneous manifestations, DH presents a unique clinical and diagnostic challenge. In this article, we seek to comprehensively delineate the clinical, histologic, and immunologic dimensions of DH, with particular emphasis on its etiopathogenic association with CD. The underlying autoimmune cascade involving the interaction between immunoglobulin A (IgA) and tissue transglutaminase is examined, with crucial implications in the pathogenesis of DH.

As understanding of immunologic mechanisms expands, the diverse spectrum of clinical presentations of DH is explored, highlighting the variability in skin lesion morphology and its correlation with histologic findings. In the therapeutic arena, conventional and emerging approaches are reviewed, ranging from dapsone-based drug therapy to nutritional and pharmacologic interventions aimed at suppressing the abnormal immune response. As research advances, it is essential to further the early diagnosis and integrated management of DH, addressing both cutaneous symptoms and systemic implications, to improve patients' quality of life and provide comprehensive and insightful clinical care.

KEYWORD: Dermatitis, Herpetiformis, skin, disease

ARTICLE DETAILS

Published On:
24 August 2023

Available on:
https://ijmscr.org/

INTRODUCTION

Dermatitis herpetiformis (DH) emerges as a distinctive dermatologic entity, finding its place in the spectrum of autoimmune diseases with a clear interconnection to celiac disease (CD). This chronic, pruritic cutaneous pathology exhibits a constellation of clinical, histopathologic and immunologic features that differentiate it from other cutaneous manifestations and highlight its unique, underlying nature. DH presents a diagnostic and therapeutic challenge that requires a thorough understanding of its etiopathogenic mechanisms and a comprehensive clinical approach.1,2

As advances in research allow us to delve deeper into the immunologic connections and clinical variability of DH, it is imperative to bring together existing knowledge to inform the medical and scientific community about this critically important skin condition. In this review, we will explore the clinical, histologic, immunologic, and therapeutic facets of DH in the interest of enriching our collective understanding and improving the ability to accurately and effectively diagnose, treat, and manage this entity.2,3

EPIDEMIOLOGY

Dermatitis herpetiformis (DH) is distinguished by its infrequent nature, with an estimated prevalence ranging from 10-39 cases per 100,000 individuals in populations of European descent. Its geographic distribution exhibits a characteristic pattern, being more prevalent in regions where celiac disease (CD) also has high rates. This intrinsic association with CD gives DH a profound clinical and

pathogenic context, as both conditions share underlying immunological and genetic similarities.3

It is essential to note that DH predominantly affects young and middle-aged adults, with a slight predominance in the male gender. Onset in childhood is uncommon, and the typical age of onset is between the second and fifth decade of life. Correlation with CD manifests in approximately 90% of DH cases, establishing a link that underscores the importance of a comprehensive evaluation of DH patients to identify possible comorbidities and associated risks.4

The clinical relevance of DH transcends its limited prevalence, given its close relationship with CD and the involvement of a triggering autoimmune response. DH is considered to be a cutaneous manifestation of gluten sensitivity, with the presence of specific autoantibodies such as anti-tissue transglutaminase IgA (anti-tTG) and anti-endomysial IgA. This profound immunologic connection raises the question of systematic evaluation of DH patients to proactively identify and manage underlying CD, thus avoiding long-term complications such as nutrient malabsorption and systemic manifestations.5,6

In addition, DH presents clinically with pruritic skin lesions, vesicles and grouped blisters, which can trigger a significant decrease in quality of life due to the physical and emotional discomfort it causes. Intense itching and recurrent occurrence of lesions often result in sleep impairment, anxiety and psychological stress in patients. Early identification and proper management of DH not only alleviates skin symptoms, but also prevents long-term complications and improves the overall well-being of the individual.6

The unique epidemiology and connection to CD make DH an entity of clinical and immunological relevance, a thorough understanding of which is critical for accurate diagnosis, effective treatment and holistic management of affected patients.6

CLINIC

Dermatitis herpetiformis (DH) engenders an eclectic palette of clinical manifestations that intersect with the pathogenesis and systemic relevance of this unique dermatologic entity. The cutaneous lesions that characterize DH are distinguished by their morphologic polymorphism and the consequent diagnostic challenge they present.7

Clinically, DH presents as papules, vesicles, blisters and erythematous rash, which tend to cluster in exposed skin areas such as elbows, knees, buttocks and lumbar region. These lesions evolve into a notoriously pruritic symptomatology, exacerbated by scratching, which may induce excoriations and secondary cutaneous erosions. The tendency for symmetrical distribution of the lesions and their episodic recurrence add a distinctive dimension to the clinical presentation of DH.7,8

The clinical importance of DH lies in several aspects. First, its intricate connection with celiac disease (CD) marks a milestone in the intersection of immunodermatology and gastroenterology, as both conditions share an autoimmune basis and share specific autoantibodies, such as anti-tissue IgA anti-tissue transglutaminase. This linkage underscores the need for a multidisciplinary evaluation and a comprehensive approach to address both cutaneous and systemic manifestations of DH and CD.8,9

In addition, the insidious and relentless pruriginosity of skin lesions can have a negative impact on patients' quality of life. Chronic pruritus can cause sleep disturbances, anxiety and a general decline in psychosocial well-being. Early identification and proper treatment not only alleviates skin symptoms, but also addresses the psychological ramifications that accompany this disease.9

The clinical relevance of DH is further deepened by its ability to serve as an indicator of gluten sensitivity and underlying celiac disease. Identification of DH may trigger further investigations to detect and optimally manage CD, avoiding the detrimental consequences of nutrient malabsorption and systemic manifestations.9,10

DH, through its polymorphous clinical morphology and intricate relationship with CD, stands out as a paradigm of the intersection between dermatology and gastroenterology. Its clinical relevance lies in the comprehensive evaluation, relief of pruritus, and early diagnosis and appropriate management of the underlying celiac disease, all of which contribute to improving the quality of life and overall well-being of affected patients.10

DIAGNOSIS

The diagnosis of dermatitis herpetiformis (DH) involves an intricate symphony of clinical, histopathological and immunological assessments that amalgamate a multidimensional approach essential for its accurate identification. The relevance of the diagnosis of DH goes beyond the mere classification of a dermatologic entity, as it reveals underlying immunologic connections, informs the association with celiac disease (CD), and triggers appropriate therapeutic interventions.11

Clinically, DH presents with pruritic and polymorphous skin lesions that require acute clinical discernment to differentiate from other dermatologic conditions that bear clinical similarities. The symmetrical distribution and tendency for clustering of lesions in specific areas add to the diagnostic challenges. The relevance of clinical evaluation lies in the early detection of these unique skin lesions, which can lead to timely diagnosis and appropriate management.11

Histopathology plays a fundamental role in the diagnostic process, showing characteristic findings such as the presence of subepidermal vesicles, neutrophilic inflammatory infiltrates and the deposition of immunoglobulin A (IgA) and complement at the dermoepidermal junction. The relevance of histopathology lies in its ability to confirm the autoimmune nature of DH and to rule out other entities with similar presentations.11

Direct immunofluorescence (DIF) emerges as an essential pillar in the diagnosis of DH, as it reveals IgA deposition in a granular arrangement along the basement membrane. These IgA deposits correlate with the clinical appearance of skin lesions, reinforcing the pathogenic connection between cutaneous manifestations and underlying immunologic abnormalities. DIF not only has diagnostic relevance, but also offers insight into the assessment of disease activity and response to treatment.11,12

The intimate correlation between DH and CD adds another dimension to the diagnosis and its clinical relevance. The identification of DH can act as a red flag for the need for further investigations aimed at detecting and managing CD, thus avoiding long-term complications associated with nutrient malabsorption and extracutaneous manifestations.13

The diagnosis of DH encompasses a range of clinical, histopathologic and immunologic approaches that combine to reveal the autoimmune nature and relationship to CD. The importance of the diagnosis lies in its ability to inform the pathogenesis, management and systemic considerations of this dermatologic entity, thereby guiding clinical practice toward effective therapeutic interventions and improving patients' quality of life.13,14

TREATMENT

The treatment of dermatitis herpetiformis (DH) stands as a field of study and practice where pharmacology, immunology and nutrition converge, with the purpose of mitigating the pruritic and erosive cutaneous manifestations, as well as addressing the intimate connection with celiac disease (CD). This therapeutic approach, characterized by its multidimensionality and relevance to improving patients' quality of life, requires a thorough understanding of the underlying pathogenic mechanisms and a thorough clinical evaluation.14,15

At the heart of the treatment of DH lies the administration of dapsone, a drug with anti-inflammatory and antipruritic properties that acts as a myeloperoxidase inhibitor in neutrophils. Dapsone, by suppressing the cutaneous inflammatory response, attenuates pruritus and promotes healing of vesicular and blistering lesions characteristic of DH. Despite its efficacy, the use of dapsone should be closely monitored due to possible hematologic and hepatic side effects, underscoring the need for close clinical monitoring during therapy.14,15

The relevance of nutrition in the treatment of DH is manifested in the rigorous adherence to a gluten-free diet. The undeniable relationship between DH and CD requires complete exclusion of gluten-containing foods to control both cutaneous and systemic manifestations. Nutritional education and counseling are essential to ensure an appropriate and sustainable diet that addresses the clinical needs and dietary concerns of the patient.16

Pharmacological and nutritional therapy is complemented by constant monitoring of immunological markers. Evaluation of serum levels of specific autoantibodies, such as anti-tissue transglutaminase IgA and anti-endomysial IgA, helps to assess therapeutic response and identify any recurrence of disease activity. This active surveillance allows individualized treatment adjustment, thus maximizing therapeutic benefits.17,18

The treatment of DH cannot be fully understood without recognizing the importance of a multidisciplinary approach to patient care. Collaboration between dermatologists, gastroenterologists and nutritionists is essential for the holistic and effective management of this entity. This comprehensive approach not only addresses cutaneous manifestations, but also considers systemic implications, which contributes to informed and insightful clinical care.18

The treatment of DH stands as a compendium of pharmacologic, nutritional, and clinical approaches aimed at attenuating skin symptoms and managing the underlying CD. The therapeutic relevance lies in its ability to improve patients' quality of life while addressing the immunological and nutritional dimensions of this complex dermatological entity and its connection to CD.19

CONCLUSION

At the culmination of this comprehensive exploration, a nuanced and profound understanding of dermatitis herpetiformis (DH) emerges, a dermatologic entity that transcends the confines of its cutaneous symptomatology and intertwines with celiac disease (CD), hinting at the complexity and multidimensionality inherent in its nature. The convergence of immunology, clinical pathology and therapeutics defines a clear narrative in the management of CD, which acquires indisputable clinical and scientific relevance.

The polymorphous clinical manifestations of DH, from pruritic vesicles to excoriative lesions, challenge diagnostic insight and underscore the need for skillful clinical evaluation to differentiate it from other dermatologic conditions. The pathologic intersection with CD establishes a deep immunologic connection, where the presence of specific autoantibodies and the relationship between IgA and tissue transglutaminase delineate the threads of underlying pathogenesis.

Accurate diagnosis of DH lies in the combination of clinical, histopathological and immunological evaluations, guiding clinical decision-making and opening the door to effective therapeutic management. In this context, the treatment of DH emerges as a dynamic field, where dapsone and gluten-free diet occupy the center of the therapeutic scenario, alleviating cutaneous symptomatology and controlling systemic dimensions, respectively. Active monitoring of immunological markers and adherence to a multidisciplinary approach ensure holistic care that responds to the complexity of this entity.

The relevance of DH in the medical and scientific landscape is undeniable. From its ability to serve as a cutaneous marker

of CD to its intricate immunologic relationship, DH transcends skin lesions to reveal deeper connections to systemic health. The multidimensionality of DH and its impact on patients' quality of life demand a comprehensive approach to its clinical management, where interdisciplinary knowledge and collaboration are crucial.

Ultimately, this tour of the immunologic, clinical, and therapeutic dimensions of DH highlights the continued need for research, medical education, and informed clinical care. With each scientific advance and each patient cared for, new layers of this complex entity are unraveled, enriching our understanding and empowering the medical community to meet the clinical challenges and improve the quality of life of those affected by dermatitis herpetiformis.

REFERENCES

I. Mendes FBR, Hissa-Elian A, De Abreu MA and Gonçalves VS, Review: dermatitis herpetiformis, An Bras Dermatol 2013; 88:594-9 .

II. Fry L, Dermatitis herpetiformis: problems, progress and prospects, European Journal of Dermatology 2002; 12(6):523-31.

III. Bolotin D, and Petronic-Rosic V, Dermatitis herpetiformis: Part ii. Diagnosis, management, and prognosis, Journal of the American Academy of Dermatology 2011; 64(6)1027-33.

IV. Caproni M, Antiga E, Melani L and Fabbri P, Guidelines for the diagnosis and treatment of dermatitis herpetiformis, Journal of the European Academy of Dermatology and Venereology 2009; 23(6):633-8.

V. Hervonen K et al, Reduced mortality in dermatitis herpetiformis: a population-based study of 476 patients, Br J Dermatol 2012; 167(6)1331-7.

VI. Bolotin D and Petronic-Rosic V, Dermatitis herpetiformis: Part i. Epidemiology, pathogenesis, and clinical presentation, J Am Acad Dermatol 2011; 64:1017-24.

VII. Bonciani D et al, Dermatitis herpetiformis: from the genetics to the development of skin lesions, Clin Dev Immunol 2012; 1:239691.

VIII. Alonso-Llamazares J, Gibson LE and Rogers RS, Clinical, pathologic, and immunopathologic features of dermatitis herpetiformis: review of the Mayo Clinic experience, Int J Dermatol 2007; 46:910-9.

IX. Lever's histopathology of the skin, 10th ed, J Cutan Pathol-Wiley Online Library, 2009.

X. Reunala TL, Dermatitis herpetiformis, Clinics in Dermatology 2001; 144:196-7.

XI. Zone JJ, Meyer LJ and Petersen MJ, Deposition of granular iga relative to clinical lesions in dermatitis herpetiformis, Arch Dermatol 1996; 132(8):912-8.

XII. Dieterich W et al, Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis, J Invest Dermatol 1999; 113(1)133-6.

XIII. Sárdy M, Kárpáti S, Merkl B, Paulsson M and Smyth N, Epidermal transglutaminase (tgase 3) is the autoantigen of dermatitis herpetiformis, J Exp Med 2002; 195(6):747-57.

XIV. Zone JJ et al, Dermatitis herpetiformis sera or goat anti-transglutaminase-3 transferred to human skin-grafted mice mimics dermatitis herpetiformis immunopathology, J Immunol 2011; 186(7):4474-80.

XV. Mobacken H, Kastrup W and Nilsson LA, Incidence and prevalence of dermatitis herpetiformis in Western Sweden, Acta Derm Venereol 1984; 64(5):400-4.

XVI. Reunala T and Lokki J, Dermatitis herpetiformis in Finland, Acta Derm Venereol 1978.

XVII. Smith JB, Tulloch JE, Meyer LJ, and Zone JJ, The incidence and prevalence of dermatitis herpetiformis in Utah, Arch Dermatol 1992; 128:1608-10.

XVIII. Lanzini A et al, Epidemiological, clinical and histopathologic characteristics of celiac disease: results of a case-finding population-based program in an Italian community, Scand J Gastroenterol 2005; 40(8)950-7.

XIX. Llorente-Alonso MJ, Fernández-Aceñero MJ and Sebastián M, Gluten intolerance: sex- and age-related features, Can J Gastroenterol 2006; 20(11)719-22.